ArticleBritish journal of haematology2025

Daratumumab and isatuximab differentially affect CD38 detection on plasma cells in myeloma: Anti-CD38 nanobody (clone JK36) and CD319 combination improve flow cytometric identification of plasma cells after targeted therapies.

Afshin Shameli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.